How have KTTAW shares performed in 2024?

Pasithea Therapeutics' stock was trading at $0.0180 at the start of the year. Since then, KTTAW stock has decreased by 22.2% and is now trading at $0.0140. View the best growth stocks for 2024 here .

How do I buy shares of Pasithea Therapeutics?

Shares of KTTAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KTTAW

Pasithea Therapeutics (KTTAW) Stock Price, News & Analysis

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)

Free KTTAW Stock Alerts

$0.01

0.00 (0.00%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.0140
▼
$0.0140
50-Day Range: $0.01
▼
$0.02
52-Week Range: $0.00
▼
$0.12

Volume: N/A
Average Volume: 9,608 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials SEC Filings Short Interest Social Media

Get Pasithea Therapeutics alerts:

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for Central Nervous System disorders, RASopathies, and other diseases. It operates through two segments, Therapeutics and Clinics. The company provides business support services to anti-depression clinics, entities, and registered healthcare providers. Its lead product candidate PAS-004, a next-generation mitogen-activated protein kinase, or MEK inhibitor designed to be macrocyclic for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 and Noonan syndrome, as well as lamin A/C cardiomyopathy and oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; PAS-002, for the treatment multiple sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

KTTAW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KTTAW Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive KTTAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:KTTAW
CUSIP: N/A
CIK: 1841330
Web: www.pasithea.com
Phone: 702-514-4174
Fax: N/A
Employees: 15
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $486,559.00
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. Lawrence Steinman BA (Age 76)
M.D., Ph.D., Co-Founder, MD & Executive Chairman
Comp: $250k
Dr. Tiago Reis Marques M.D. (Age 47)
Ph.D., CEO & Director
Comp: $539.25k
Mr. Daniel H. Schneiderman (Age 46)
Chief Financial Officer
Comp: $327.91k
Dr. Yassine Bendiabdallah Ph.D. (Age 40)
COO & Head of UK Clinics
Dr. Graeme Currie Ph.D.
Chief Development Officer

Key Competitors

View All Competitors

KTTAW Stock Analysis - Frequently Asked Questions

How have KTTAW shares performed in 2024?: Pasithea Therapeutics' stock was trading at $0.0180 at the start of the year. Since then, KTTAW stock has decreased by 22.2% and is now trading at $0.0140.
View the best growth stocks for 2024 here.
How do I buy shares of Pasithea Therapeutics?: Shares of KTTAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KTTAW) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial